Literature DB >> 30718019

Prognostic Validation Using GesEPOC 2017 Severity Criteria.

Carlos Cabrera López1, Ciro Casanova Macario2, José María Marín Trigo3, Juan P de-Torres4, Rebeca Sicilia Torres5, Jesús María González6, Francesca Polverino7, Miguel Divo7, Víctor Pinto Plata8, Javier Zulueta4, Francisco Javier Callejas9, Bartolomé Celli7.   

Abstract

INTRODUCTION: The Spanish COPD guidelines (GesEPOC) have been recently modified. The aim of this study is to assess this revision and evaluate the prognosis of patients according to the new classification of severity.
METHODS: A total of 700 COPD patients (83.9% men) were prospectively followed up for a mean period of 5 years in tertiary hospitals in Spain and the USA. Anthropometric data, lung function tests, dyspnea (according to the mMRC scale), BODE and Charlson index were collected. We calculated mortality at 5 years following the risk criteria proposed by the new GesEPOC.
RESULTS: Mean age was 66±9.6 years and mean FEV1% was 59.7±20.2. The proportion of patients in the low-risk group was 40.43%. Patients in the high-risk group had a significantly higher BODE index than those in the low-risk group (2.92±0,66 vs. 0.52±1.91, p<0.001), while the Charlson index score was similar in both groups. Mortality at 60 months was significantly higher in the high-risk group (31.7% vs. 15.5%, p<0.001). Dyspnea and FEV1% were also independent predictors of mortality (p<0.001), and neither was inferior to the risk classification proposed by GesEPOC.
CONCLUSIONS: The new severity index proposed by GesEPOC accurately predicts 5-year mortality. However, dyspnea and FEV1% have the same strength in predicting mortality.
Copyright © 2018 SEPAR. Publicado por Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  COPD; EPOC; GesEPOC; Mortalidad; Mortality; Prognosis; Pronóstico; Riesgo; Risk

Mesh:

Year:  2019        PMID: 30718019     DOI: 10.1016/j.arbres.2018.12.002

Source DB:  PubMed          Journal:  Arch Bronconeumol (Engl Ed)        ISSN: 0300-2896            Impact factor:   4.872


  2 in total

1.  The TAGA Study: A Study of Factors Determining Aortic Diameter in Families at High Risk of Abdominal Aortic Aneurysm Reveal Two New Candidate Genes.

Authors:  Olga Peypoch; Ferran Paüls-Vergés; Miquel Vázquez-Santiago; Jaime Dilme; Jose Romero; Jordi Giner; Vicente Plaza; Jose Roman Escudero; Jose Manuel Soria; Mercedes Camacho; Maria Sabater-Lleal
Journal:  J Clin Med       Date:  2020-04-24       Impact factor: 4.241

Review 2.  The role of long-acting muscarinic antagonist/long-acting β agonist fixed-dose combination treatment for chronic obstructive pulmonary disease in China: a narrative review.

Authors:  Ji'an Zhou; Jing Zhang; Min Zhou; Jingqing Hang; Min Zhang; Fengfeng Han; Huili Zhu
Journal:  J Thorac Dis       Date:  2021-11       Impact factor: 3.005

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.